These trials completed more than 12 months ago and should have reported results. Some have, some have not.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Completed, but no date Terminated 2004-004557-25 Phase II study of Brostallicin a(PNU- 166196) and Cisplatin (CDDP) in Adult Patients with Recurrent Squamous Cell Carcinoma of the Head and Neck (SCCHN)preceded by a dose-escalation component bad-data
Reported results 2005-000731-26 Nemorubicin hydrochloride (PNU-152243A) administered via intra-hepatic artery in combination with cisplatin in adult patients with unresectable hepatocellular carcinoma: phase II study preceeded by a ... 2012-04-19 due-trials
Completed, but no date 2005-004200-36 Phase II exploratory study of brostallicin PNU-166196A as third/fourth line chemoterapy in adult patients with advanced/metastatic colorectal cancer CRC . bad-data
Completed, but no date 2005-005646-39 Phase II exploratory study of brostallicin PNU-166196A in patients with ovarian cancer resistant/refractory to platinum based chemotherapy. bad-data
Not reported Terminated 2006-000798-31 Phase II randomized study of nemorubicin hydrochloride (PNU-152243A) or doxorubicin administered in adult patients with unresectable hepatocellular carcinoma 2007-05-16 due-trials
Not reported 2006-001861-40 Randomized phase II study of brostallicin (PNU-166196A) versus doxorubicin as first line chemotherapy in patients with advanced or metastatic soft tissue sarcoma 2009-12-08 due-trials
Exempt, with results 2006-003193-10 A phase I/II study of oral PHA-848125AC given daily for 14 consecutive days every 3 weeks in recurrent malignant glioma 2012-08-31 not-yet-due
Reported results 2006-003772-35 Phase II study of PHA-739358 administered by a 24-hour IV infusion every 14 days in advanced/metastatic breast, ovarian, colorectal, pancreatic, small cell lung and non small cell lung cancers. 2012-08-25 due-trials
Reported results 2006-006136-21 A Phase II Study of PHA-739358 in Patients with Metastatic Hormone Refractory Prostate Cancer. 2011-03-23 due-trials
Completed, but no date, and reported results Terminated 2006-006881-40 A pilot Phase II study of PHA-739358 in patients with Chronic Myeloid Leukemia relapsing on Gleevec or c-ABL therapy bad-data
Reported results 2007-005425-30 An Exploratory Phase II Study of PHA-739358 in Patients with Multiple Myeloma Harbouring the t (4;14) translocation with or without FGFR3 Expression 2009-09-21 due-trials
Completed, but no date, and reported results 2008-005831-13 Phase II study of PHA-848125AC as second line-treatment in pemetrexed pre-treated malignant pleural mesothelioma patients bad-data
Reported results 2009-014338-79 PHASE II STUDY OF ORAL PHA-848125AC IN PATIENTS WITH THYMIC CARCINOMA PREVIOUSLY TREATED WITH CHEMOTHERAPY 2018-12-17 due-trials
Completed, but no date, and reported results Terminated 2013-000344-25 Phase II study of oral PHA-848125AC in patients with malignant thymoma previously treated with multiple lines of chemotherapy Studio di fase II di PHA-848125AC somministrato per via orale in pazien... bad-data
Exempt 2018-002793-47 A Phase I/II Study of NMS-03592088, a FLT3, KIT and CSF1R Inhibitor, in Patients with Relapsed or Refractory AML or CMML Studio di fase I/II con NMS-03592088, un inibitore di FLT3, KIT e CSF1R, in ... not-yet-due
Exempt 2020-001002-26 Phase I/II study on safety and efficacy of NMS-01940153E in adult patients with unresectable hepatocellular carcinoma (HCC) previously treated with systemic therapy. Studio di fase I/II sulla sicur... not-yet-due
Exempt 2020-003417-35 A Phase I/II Combination Study of NMS-03305293 and Temozolomide in Adult Patients with Recurrent Glioblastoma not-yet-due
Exempt Terminated 2021-005013-14 A Phase I/II Combination Study of NMS-03592088 And Azacitidine for the Treatment of Patients With FLT3-Mutated AML with Relapsed /Refractory Disease or Who Are Unfit For Intensive Chemotherapy, or of ... 2023-06-16 not-yet-due